Anti-EBV Latent Membrane Protein 1 [CS 1-4]

Anti-EBV (CS1) is a latent membrane protein 1 antibody, which detects a specific epitope upon LMP fusion protein in B-cell transformations, following EBV infection.

Contributors

Inventor Institute
Martin Rowe University of Birmingham
Cat. #: 151471
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Microbiology
Application: IHC ; IHC ; IF ; IP ; WB
Target: Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)
Reactivity: Virus
Clone: CS 1-4
Host: Mouse
Class: Monoclonal
Product description: Anti-EBV (CS1) is a latent membrane protein 1 antibody, which detects a specific epitope upon LMP fusion protein in B-cell transformations, following EBV infection.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Molecular weight: 57-66 kDa
Immunogen: P03230
Immunogen Uniprot ID: P03230
Myeloma used: P3X63Ag8.653
Target background: A combination of four pooled antibodies which collectively detect the latent membrane protein (LMP) of EBV, an important effector protein in B-cell transformation under EBV infection, across 20 geographically distinct EBV isolates. EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. LMP1 can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells. These antibodies were created to examine various aspects of LMP expression in B-cell lines transformed in vitro, detecting LMPs from 20 geographically varied EBV isolates.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Ye et al. 2020. J Cancer. 11(5):1257-1269. PMID: 31956372.

Shi et al. 2019. Theranostics. 9(9):2424-2438. PMID: 31131045.

Wang et al. 2017. Virol Sin. 32(5):423-430. PMID: 29116594.

Martin et al. 2016. J Virol. 90(19):8520-30. PMID: 27440880.

Castrale et al. 2011. J Transplant. 2011:865957. PMID: 21559262.

Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.

Localization of the Epstein-Barr virus protein LMP 1 to exosomes.

Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.

Pyothorax-associated lymphoma: a review of 106 cases.

Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.

Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.

Pyothorax-associated lymphoma: description of the first two cases detected in Italy.

Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.

Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.

Rowe et al. 1987. J Gen Virol. 68 ( Pt 6):1575-86. PMID: 2438376.

Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151015 Anti-CyclinA [E70.1] Key Info View Tool
151017 Anti-MBP [R29.6] Key Info View Tool
151027 Anti-HSVICP8 [10A3] Key Info View Tool
151029 Anti-HSVICP8 [11E2] Key Info View Tool
151031 Anti-RuvA [RuvA 12C6] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.